GeneThera, Inc. (GTHR)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | - USD | -100.0% |
| 2021 | 1 Million USD | 36.27% |
| 2020 | 740.61 Thousand USD | 0.2% |
| 2019 | 739.15 Thousand USD | -81.18% |
| 2018 | 3.92 Million USD | 548.3% |
| 2017 | 605.7 Thousand USD | -10.94% |
| 2016 | 680.06 Thousand USD | -24.51% |
| 2015 | 900.89 Thousand USD | 48.03% |
| 2014 | 608.6 Thousand USD | -44.67% |
| 2013 | 1.09 Million USD | -24.22% |
| 2012 | 1.45 Million USD | 30.26% |
| 2011 | 1.11 Million USD | 130.77% |
| 2010 | 482.9 Thousand USD | -60.48% |
| 2009 | 1.22 Million USD | -38.9% |
| 2008 | 1.99 Million USD | 112.75% |
| 2007 | 939.82 Thousand USD | -42.43% |
| 2006 | 1.63 Million USD | -53.91% |
| 2005 | 3.54 Million USD | -21.11% |
| 2004 | 4.49 Million USD | 75.73% |
| 2003 | 2.55 Million USD | 152.09% |
| 2002 | 1.01 Million USD | 200.19% |
| 2001 | 337.66 Thousand USD | 46155.48% |
| 2000 | 730.00 USD | -99.83% |
| 1999 | 438.61 Thousand USD | 54.21% |
| 1998 | 284.43 Thousand USD | 1.58% |
| 1997 | 280 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q3 | 125.01 Thousand USD | -15.17% |
| 2022 Q1 | 132.18 Thousand USD | -52.4% |
| 2022 FY | - USD | -100.0% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q2 | 147.38 Thousand USD | 11.49% |
| 2021 Q3 | 242.26 Thousand USD | -14.91% |
| 2021 Q2 | 284.72 Thousand USD | 39.17% |
| 2021 Q4 | 277.72 Thousand USD | 14.64% |
| 2021 Q1 | 204.59 Thousand USD | 54.85% |
| 2021 FY | 1 Million USD | 36.27% |
| 2020 Q1 | 141.7 Thousand USD | -40.73% |
| 2020 Q2 | 194.06 Thousand USD | 36.95% |
| 2020 Q3 | 272.72 Thousand USD | 40.53% |
| 2020 Q4 | 132.12 Thousand USD | -51.55% |
| 2020 FY | 740.61 Thousand USD | 0.2% |
| 2019 Q3 | 204.32 Thousand USD | 48.61% |
| 2019 Q2 | 137.49 Thousand USD | -13.1% |
| 2019 Q1 | 158.22 Thousand USD | -94.93% |
| 2019 Q4 | 239.1 Thousand USD | 17.02% |
| 2019 FY | 739.15 Thousand USD | -81.18% |
| 2018 Q3 | 313.55 Thousand USD | 0.77% |
| 2018 Q1 | 202.17 Thousand USD | 48.33% |
| 2018 FY | 3.92 Million USD | 548.3% |
| 2018 Q4 | 3.12 Million USD | 895.1% |
| 2018 Q2 | 311.16 Thousand USD | 53.91% |
| 2017 Q3 | 109.98 Thousand USD | -4.24% |
| 2017 FY | 605.7 Thousand USD | -10.94% |
| 2017 Q1 | 244.56 Thousand USD | 133.8% |
| 2017 Q2 | 114.85 Thousand USD | -53.04% |
| 2017 Q4 | 136.29 Thousand USD | 23.92% |
| 2016 Q1 | 260.75 Thousand USD | 29.65% |
| 2016 FY | 680.06 Thousand USD | -24.51% |
| 2016 Q4 | 104.6 Thousand USD | -15.2% |
| 2016 Q3 | 123.35 Thousand USD | -35.54% |
| 2016 Q2 | 191.35 Thousand USD | -26.62% |
| 2015 FY | 900.89 Thousand USD | 48.03% |
| 2015 Q1 | 348.88 Thousand USD | 217.83% |
| 2015 Q2 | 147.53 Thousand USD | -57.71% |
| 2015 Q3 | 203.36 Thousand USD | 37.84% |
| 2015 Q4 | 201.12 Thousand USD | -1.1% |
| 2014 Q3 | 118.76 Thousand USD | -44.53% |
| 2014 Q1 | 165.97 Thousand USD | -11.61% |
| 2014 FY | 608.6 Thousand USD | -44.67% |
| 2014 Q4 | 109.77 Thousand USD | -7.57% |
| 2014 Q2 | 214.09 Thousand USD | 28.99% |
| 2013 Q2 | 282.05 Thousand USD | 1.23% |
| 2013 FY | 1.09 Million USD | -24.22% |
| 2013 Q4 | 187.77 Thousand USD | -46.97% |
| 2013 Q3 | 354.07 Thousand USD | 25.54% |
| 2013 Q1 | 278.61 Thousand USD | -22.17% |
| 2012 Q1 | 515.11 Thousand USD | 170.12% |
| 2012 Q2 | 337.57 Thousand USD | -34.47% |
| 2012 FY | 1.45 Million USD | 30.26% |
| 2012 Q4 | 357.98 Thousand USD | 48.59% |
| 2012 Q3 | 240.91 Thousand USD | -28.63% |
| 2011 FY | 1.11 Million USD | 130.77% |
| 2011 Q1 | 142.47 Thousand USD | -19.12% |
| 2011 Q4 | -734.67 Thousand USD | -148.13% |
| 2011 Q2 | 186.66 Thousand USD | 31.01% |
| 2011 Q3 | 1.52 Million USD | 717.76% |
| 2010 FY | 482.9 Thousand USD | -60.48% |
| 2010 Q1 | 108.52 Thousand USD | 74.99% |
| 2010 Q2 | 89.79 Thousand USD | -17.26% |
| 2010 Q4 | 176.16 Thousand USD | 62.47% |
| 2010 Q3 | 108.42 Thousand USD | 20.75% |
| 2009 Q1 | 313.91 Thousand USD | 120.94% |
| 2009 Q3 | 549.91 Thousand USD | 85.82% |
| 2009 Q2 | 295.93 Thousand USD | -5.73% |
| 2009 Q4 | 62.01 Thousand USD | -88.72% |
| 2009 FY | 1.22 Million USD | -38.9% |
| 2008 Q4 | -1.49 Million USD | -148.06% |
| 2008 Q2 | 158.49 Thousand USD | -21.03% |
| 2008 Q1 | 200.69 Thousand USD | 12.9% |
| 2008 Q3 | 3.11 Million USD | 1867.87% |
| 2008 FY | 1.99 Million USD | 112.75% |
| 2007 Q1 | 219.75 Thousand USD | -57.05% |
| 2007 FY | 939.82 Thousand USD | -42.43% |
| 2007 Q4 | 177.76 Thousand USD | -0.61% |
| 2007 Q3 | 178.86 Thousand USD | -52.91% |
| 2007 Q2 | 379.8 Thousand USD | 72.84% |
| 2006 Q3 | 508.29 Thousand USD | 25.51% |
| 2006 Q4 | 511.61 Thousand USD | 0.65% |
| 2006 FY | 1.63 Million USD | -53.91% |
| 2006 Q1 | 240.29 Thousand USD | -41.06% |
| 2006 Q2 | 404.96 Thousand USD | 68.53% |
| 2005 FY | 3.54 Million USD | -21.11% |
| 2005 Q1 | 2.21 Million USD | 119.26% |
| 2005 Q2 | 406.01 Thousand USD | -81.66% |
| 2005 Q3 | 613.52 Thousand USD | 51.11% |
| 2005 Q4 | 407.71 Thousand USD | -33.55% |
| 2004 Q4 | -11.49 Million USD | -4310.76% |
| 2004 Q3 | 272.92 Thousand USD | -98.19% |
| 2004 Q2 | 15.09 Million USD | 2363.95% |
| 2004 Q1 | 612.72 Thousand USD | -70.44% |
| 2004 FY | 4.49 Million USD | 75.73% |
| 2003 Q1 | 83.47 Thousand USD | -53.93% |
| 2003 FY | 2.55 Million USD | 152.09% |
| 2003 Q4 | 2.07 Million USD | 948.03% |
| 2003 Q3 | 197.8 Thousand USD | -1.59% |
| 2003 Q2 | 201 Thousand USD | 140.8% |
| 2002 Q4 | 181.17 Thousand USD | -13.85% |
| 2002 FY | 1.01 Million USD | 200.19% |
| 2002 Q1 | 287.3 Thousand USD | -14.92% |
| 2002 Q2 | 334.87 Thousand USD | 16.56% |
| 2002 Q3 | 210.3 Thousand USD | -37.2% |
| 2001 FY | 337.66 Thousand USD | 46155.48% |
| 2001 Q4 | 337.66 Thousand USD | 312.58% |
| 2001 Q3 | 81.84 Thousand USD | -61.29% |
| 2001 Q2 | 211.43 Thousand USD | 312.91% |
| 2001 Q1 | 51.2 Thousand USD | 118.62% |
| 2000 Q1 | 110.67 Thousand USD | -57.43% |
| 2000 Q2 | 124.15 Thousand USD | 12.17% |
| 2000 Q3 | 44.83 Thousand USD | -63.89% |
| 2000 Q4 | -274.95 Thousand USD | -713.28% |
| 2000 FY | 730.00 USD | -99.83% |
| 1999 Q3 | 10 Thousand USD | -85.71% |
| 1999 Q1 | 100 Thousand USD | 150.0% |
| 1999 FY | 438.61 Thousand USD | 54.21% |
| 1999 Q4 | 260 Thousand USD | 2500.0% |
| 1999 Q2 | 70 Thousand USD | -30.0% |
| 1998 FY | 284.43 Thousand USD | 1.58% |
| 1998 Q4 | 40 Thousand USD | 0.0% |
| 1997 FY | 280 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 100.0% |
| Nascent Biotech, Inc. | 2.22 Million USD | 100.0% |
| Rebus Holdings, Inc. | 664 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 100.0% |
| Qrons Inc. | 643.67 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 13.54 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 85.61 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 100.0% |
| Mesoblast Limited | 5.9 Million USD | 100.0% |
| Marizyme, Inc. | 19.23 Million USD | 100.0% |
| Genus plc | 147.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 100.0% |
| Pharming Group N.V. | 225.49 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 100.0% |
| ContraFect Corporation | 56.88 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 100.0% |
| IMV Inc. | 37.7 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 567.42 USD | 100.0% |
| ONE Bio Corp. | 6.44 Million USD | 100.0% |
| Accustem Sciences Inc. | 3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 531.96 Thousand USD | 100.0% |
| Q BioMed Inc. | 3.43 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 100.0% |
| Biomind Labs Inc. | 994.18 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 100.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 100.0% |
| GB Sciences, Inc. | 1.42 Million USD | 100.0% |
| Alpha Cognition Inc. | 9.7 Million USD | 100.0% |
| HST Global, Inc. | 140.9 Thousand USD | 100.0% |
| CSL Limited | 3.44 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 100.0% |
| Halberd Corporation | 74.84 Thousand USD | 100.0% |
| Enzolytics Inc. | 2.17 Million USD | 100.0% |
| Agentix Corp. | 1.37 Million USD | 100.0% |
| Resverlogix Corp. | 12.71 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 1.53 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 100.0% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 100.0% |
| AVAX Technologies, Inc. | 7.31 Million USD | 100.0% |
| Zenith Capital Corp. | 8.94 Million USD | 100.0% |
| Genscript Biotech Corporation | 825.34 Million USD | 100.0% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 100.0% |
| Kadimastem Ltd | 2.41 Million USD | 100.0% |
| Helix BioMedix, Inc. | 1.97 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 100.0% |
| BioStem Technologies, Inc. | 22.97 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 100.0% |
| LadRx Corporation | 3.81 Million USD | 100.0% |
| Cell Source, Inc. | 4.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.46 Million USD | 100.0% |
| Affymax, Inc. | 39.38 Million USD | 100.0% |
| Itoco Inc. | 919.14 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 100.0% |
| Mobile Lads Corp. | 554.54 Thousand USD | 100.0% |
| CytoDyn Inc. | 18.05 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 100.0% |
| SYBLEU INC | 160.87 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 100.0% |
| International Stem Cell Corporation | 5.27 Million USD | 100.0% |
| Bioxytran, Inc. | 3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 100.0% |
| Neutra Corp. | 243.82 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 100.0% |
| PureTech Health plc | 144.59 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 100.0% |
| IXICO plc | 4.7 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 100.0% |
| CSL Limited | 3.89 Billion USD | 100.0% |
| Cellectis S.A. | 97.32 Million USD | 100.0% |